Having trouble accessing articles? Reset your cache.

You say you want a Revolution? Oncology company is latest to post big gain after IPO

Revolution’s first day performance suggests appetite for new biotech listings continues unabated in 2020, as investors’ demand for the cancer company’s shares rose both before and after its offering priced.

Revolution Medicines Inc. (NASDAQ:RVMD) raised $238 million through the sale of 14 million shares at $17, giving it a postmoney valuation of

Read the full 518 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE